Podcasts about prova education

CME credits: 0.25 Valid until: 23-05-2026 Claim your CME credit at https://reachmd.com/programs/cme/expert-perspectives-from-aua-2025-contextualizing-the-evolving-landscape-of-bladder-cancer/33076/ This online CME program features expert discussions on new research presented at AUA 2025. Drs. Neal Shore and Sarah Psutka explore emerging data on treatment strategies for high-risk BCG-naïve and BCG-unresponsive non–muscle invasive bladder cancer (NMIBC). They also highlight advances in biomarker-directed therapies, including investigational agents targeting HER2 and FGFR alterations. The program emphasizes the clinical relevance and practical application of these findings, offering clinicians actionable insights on evolving bladder cancer care.=

CME credits: 0.75 Valid until: 30-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/treatment-advances-in-generalized-myasthenia-gravis-a-pathophysiology-driven-framework-leveraging-fcrn-therapeutics/29537/ Traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial for many patients in the short term but often come with unacceptable side effects. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) has created a groundbreaking paradigm shift in our approach to both the short- and longer-term management of affected patients. Join Drs. Vera Bril and Neelam Goyal as they take a deep dive into this topic and discuss how FcRn inhibitors are changing the therapeutic landscape of gMG.=

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/a-scientific-look-at-fcrn-antagonists-mechanisms-of-action-explained/32730/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/living-with-gmg-navigating-personal-professional-and-mental-health-challenges/32726/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/diagnostic-advances-in-gmg-effective-tools-and-techniques/32727/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/autoantibodies-explained-anti-achr-anti-musk-and-their-diagnostic-role/32728/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/traditional-mg-treatments-balancing-benefits-risks-and-side-effect-management/32729/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 0.75 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/treatment-advances-in-generalized-myasthenia-gravis-clinical-and-laboratory-criteria-for-diagnosis-and-optimal-treatment-selection/29533/ The adult and pediatric diagnostic and treatment landscapes of generalized myasthenia gravis (gMG) are both similar and different. While current traditional therapies are often effective in the short term, selecting the most appropriate short- and longer-term treatment for each patient, whether adult or pediatric, brings with it unique individual challenges. These challenges include how best to utilize newer targeted agents in the treatment of gMG, such as the neonatal Fc receptor (FcRn) inhibitors. Join Drs. Vera Bril and Jonathan Strober as they tackle these issues from both the adult and pediatric perspective.=

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/new-frontiers-in-mg-how-fcrn-antagonists-are-changing-mg-therapy/32731/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/ocular-to-generalized-mg-how-and-why-the-disease-evolves/32733/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/preventing-myasthenic-crisis-early-signs-and-critical-interventions/32734/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/precision-medicine-for-gmg-tailoring-treatments-based-on-patient-profiles/32735/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-side-effects-in-fcrn-therapy-best-practices-for-gmg/32732/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 0.25 Valid until: 25-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/second-line-solutions-in-metastatic-tnbc-adc-selection-sequencing-and-safety/32680/ When choosing an antibody-drug conjugate (ADC) for the second-line treatment of triple-negative breast cancer (TNBC), efficacy, sequencing, and management of toxicities are key. Do you know how best to choose a therapy for your patients? Our experts have the answers and strategies you need! =

CME credits: 0.25 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/advancing-multidisciplinary-care-in-tgct-integrating-systemic-therapies-and-surgical-approaches/29871/ In this activity, a medical oncologist and orthopedic surgeon discuss evidence-based surgical and systemic therapy approaches for the treatment of tenosynovial giant cell tumors (TGCT). Topics include differentiating TGCT by presentation; surgical candidacy, approaches, and limitations; systemic treatment options with CSF1R inhibitors; and considerations for treatment selection with surgical, nonsurgical, or combination interventions. A patient case example is used to demonstrate optimal multidisciplinary and patient-centered treatment considerations and selection. Strategies for multidisciplinary collaboration to ensure comprehensive monitoring and effective disease management are also explored. Tune in to find out how to enhance the collaborative capacity of multidisciplinary teams in developing individualized, patient-centered treatment plans for patients with TGCT. Vimseltinib is now FDA-approved for adult patients with symptomatic TGCT, for which surgical resection will potentially cause worsening functional limitation or severe morbidity. This activity was recorded prior to this FDA approval.​=

CME credits: 1.25 Valid until: 31-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/pharmacotherapy-in-obesity-current-and-emerging-options/29932/ Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies available for healthcare professionals so they can optimize patient outcomes. Our series of micro learning activities will provide tips and tools for the implementation of key obesity interventions, including nutritional, physical, behavioral, and pharmacological approaches. Partner with your patients and recognize the importance of treating obesity like any other chronic condition.

CME credits: 1.25 Valid until: 31-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-power-of-shared-decision-making-in-obesity-care/29935/ Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies available for healthcare professionals so they can optimize patient outcomes. Our series of micro learning activities will provide tips and tools for the implementation of key obesity interventions, including nutritional, physical, behavioral, and pharmacological approaches. Partner with your patients and recognize the importance of treating obesity like any other chronic condition.

CME credits: 1.25 Valid until: 31-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-power-of-teamwork-multidisciplinary-obesity-care/29934/ Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies available for healthcare professionals so they can optimize patient outcomes. Our series of micro learning activities will provide tips and tools for the implementation of key obesity interventions, including nutritional, physical, behavioral, and pharmacological approaches. Partner with your patients and recognize the importance of treating obesity like any other chronic condition.

CME credits: 1.25 Valid until: 31-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/personalized-obesity-management-a-comprehensive-approach/29933/ Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies available for healthcare professionals so they can optimize patient outcomes. Our series of micro learning activities will provide tips and tools for the implementation of key obesity interventions, including nutritional, physical, behavioral, and pharmacological approaches. Partner with your patients and recognize the importance of treating obesity like any other chronic condition.

CME credits: 1.00 Valid until: 31-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/recent-guidelines-updates-implications-to-practice/26659/ This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.

CME credits: 1.25 Valid until: 31-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/breaking-the-bias-addressing-stigma-in-obesity-care/29931/ Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies available for healthcare professionals so they can optimize patient outcomes. Our series of micro learning activities will provide tips and tools for the implementation of key obesity interventions, including nutritional, physical, behavioral, and pharmacological approaches. Partner with your patients and recognize the importance of treating obesity like any other chronic condition.

CME credits: 1.25 Valid until: 31-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/diagnosing-obesity-beyond-bmi/29930/ Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies available for healthcare professionals so they can optimize patient outcomes. Our series of micro learning activities will provide tips and tools for the implementation of key obesity interventions, including nutritional, physical, behavioral, and pharmacological approaches. Partner with your patients and recognize the importance of treating obesity like any other chronic condition.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/emerging-immunotherapy-combination-strategies-in-genitourinary-malignancies/29201/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/insights-from-global-key-opinion-leaders-on-optimizing-patient-care-in-genitourinary-malignancies/29202/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/incorporation-of-guideline-recommendations-into-the-frontline-care-of-a-patient-with-mcrpc-who-is-naive-to-both-docetaxel-and-novel-hormone-therapy/29197/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/emerging-targeted-therapy-combination-strategies-in-genitourinary-malignancies/29200/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommended-second-line-treatment-following-an-immune-checkpoint-inhibitor-in-renal-cell-carcinoma/29199/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommended-first-line-treatment-with-immunotherapy-and-targeted-therapy-combinations-in-renal-cell-carcinoma/29198/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-driving-guideline-recommendations-for-frontline-immunotherapy-based-combination-regimens-in-metastatic-urothelial-cancer/29193/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommendations-for-first-line-treatment-intensification-with-parp-inhibitor-combinations-in-patients-with-metastatic-castration-resistant-prostate-cancer/29196/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-driving-guideline-recommendations-for-monotherapy-in-the-second-line-or-later-setting-in-metastatic-urothelial-cancer/29194/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/incorporation-of-guideline-concordant-care-for-first-line-treatment-of-a-patient-with-metastatic-urothelial-carcinoma/29195/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 0.25 Valid until: 06-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-weight-of-recurrence-navigating-multidisciplinary-care-planning-in-recurringmetastatic-cervical-cancer/29168/ In recent years, the treatment landscape for recurrent or metastatic cervical cancer has undergone significant shifts with FDA approvals of first-line pembrolizumab plus platinum-doublet with or without bevacizumab and second-line tisotumab vedotin. The introduction of frontline immune checkpoint blockade also added to the challenges faced by clinicians as they choose optimal regimens for their patients. In this online CME activity, Dr. Coleman and Dr. Slomovitz offer strategies for treatment selection and sequencing with immune checkpoint inhibitors and antibody-drug conjugates for relapsed cervical cancer. Tune in to hear their expert perspectives on biomarker testing, clinical trial evidence, and multidisciplinary management of adverse events associated with these therapies to make sure your patients are getting the most out of these advances. =

CME credits: 1.50 Valid until: 04-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-treatment-and-management-of-mash-more-options-more-decisions/24277/ Join us for a CME online broadcast replay of a live satellite symposium from ACG 2024, where experts discuss MASLD/MASH, a serious disease that is both chronic and progressive. What's most concerning is that MASLD/MASH will soon be the most common indication for liver transplantation and a major driver of the development of liver cancer. Until recently there was no liver-directed therapy for this disease, and the metabolic benefits of pharmacologic modification of body weight were underappreciated. This activity will also provide practical interactive discussions of cardiometabolic pathophysiologic pathways; early identification and risk stratification; advances in treatment; monitoring for disease progression; and long-term medical management, including the role of incretin agonists.=

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/dont-forget-theres-a-sleepy-patient-behind-those-numbers/29112/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/pbc-is-risky-business/29109/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/pbc-target-practice-normalization-is-the-new-norm/29110/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/initiating-second-line-therapy-what-when-and-then-what/29111/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/dont-forget-theres-an-itchy-patient-behind-those-numbers/29113/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-treatment-of-pbc-part-1/29114/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-treatment-of-pbc-part-2/29115/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

CME credits: 1.00 Valid until: 30-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/underlying-mediators-of-immune-dysregulation-in-ted/26958/ Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves' disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.

CME credits: 1.00 Valid until: 30-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/ted-clinical-trials-spotlight/26965/ Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves' disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.

CME credits: 1.00 Valid until: 30-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/arvo-recap-whats-new-in-ted/26964/ Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves' disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.

CME credits: 1.00 Valid until: 30-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-future-of-ted/26963/ Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves' disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.

CME credits: 1.00 Valid until: 30-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/ted-current-treatments-current-challenges/26962/ Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves' disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.

CME credits: 1.00 Valid until: 30-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/diagnostic-challenges-of-ted-what-eye-care-specialists-need-to-know/26961/ Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves' disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.

CME credits: 1.00 Valid until: 30-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/diagnostic-challenges-of-ted-what-general-eye-care-providers-need-to-know/26960/ Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves' disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.

CME credits: 1.00 Valid until: 30-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/diagnostic-challenges-of-ted-what-endocrinologists-need-to-know/26959/ Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves' disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.

CME credits: 1.00 Valid until: 30-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-burden-of-ted/26957/ Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves' disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.